asco乳腺癌内分泌治疗进展刘冬耕PPT.pptx

2013 ASCO 乳腺癌内分泌治疗进展 ;内容;;20,187 women with ER-positive or ER-unknown disease randomised in 5 trials of 10 vs 5 years of tamoxifen: ;aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer;10 vs 5 years of tamoxifen: Recurrence by year of follow-up;10 vs 5 years of tamoxifen: Breast Cancer Death by Treatment Allocation;10 vs 5 years of tamoxifen: Death after recurrence by year of follow-up;10 vs 5 years of tamoxifen: Death Without Recurrence by Treatment;10 vs 5 years of tamoxifen: All cause mortality by treatment;10 vs 5 years of tamoxifen: Overall survival by treatment and year of follow-up;10 vs 5 years of tamoxifen: Overall survival by treatment and year of follow-up;Main risk: endometrial cancers: absolute hazard 0.5%,;ATLAS: 6846 women, ER+, 10 vs 5 years tamoxifen;10 yrs vs 5 yrs BREAST CANCER MORTALITY IN ER+ rate ratio* by period in aTTom and ATLAS;ER+ 10 yrs vs 5 yrs OVERALL SURVIVALrate ratio* by period in aTTom and ATLAS; Conclusions;ATLAS:10 years of tamoxifen vs 5:(Adjuvant Tamoxifen - Longer Against Shorter);Results：;ATLAS：10 years of tamoxifen vs 5:;;ER+：他莫昔芬10年 vs. 5年治疗对副反应与乳腺癌死亡率的作用; 绝经后HR阳性EBC,延长辅助内分泌治疗 MA.17 试验设计;DFS and OS;延长辅助内分泌治疗:Letrozole After 5 Years of Tamoxifen;Goss PE, et al. SABCS 2005. Abstract 16.;Goss PE, et al. SABCS 2005. Abstract 16.;The hazard ratios (HRs) of letrozole and placebo from the IPCW analyses(MA17);延长辅助内分泌治疗:Exemestane After 5 Years of Tamoxifen;NCCN 2013 辅助内分泌治疗;HR+进展期乳腺癌治疗进展;Treatment Guidelines for HR+ Advanced Breast Cancer: Second-Line Endocrine Therapy;PI3K;II期临床试验(Study 2222):新辅助： 来曲唑 ± 依维莫司;TAMRAD: II期临床试验 他莫昔芬+依维莫司在HR+进展期乳腺癌;TAMRAD: II期临床试验 他莫昔芬+依维莫司在HR+进展期乳腺癌;BOLERO-2: NSAI进展的ABC：EXE ± EVE III期临床试验;BOLERO-2: 患者基线特征;BOLERO-2: PFS最终分析结果(A) 当地评估(B) 中央评估;亚洲女性乳腺癌的发病特点;BOLERO-2 (18个月随访): PFS在亚洲及非亚洲患者中均延长2 倍以上;BOLERO-2: PFS 亚组分析;BOLERO-2: PFS 亚组分析（续）;BOLERO-2: PFS 亚组分析(A) 内脏转移, (B) 无内脏转移, (C) 仅有骨转移;B